A comparison of health care use after severe COVID-19, respiratory syncytial virus, and influenza in children

Vilde Bergstad Larsen[1], Ketil Størdal[2,3], Kjetil Telle[1], Fredrik Methi[1], Karin Magnusson[1,4]

[1]Norwegian Institute of Public Health, Cluster for Health Services Research, Oslo, Norway.

[2]Department of Pediatric Research, University of Oslo, Oslo, Norway.

[3]Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

[4]Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Orthopaedics, Clinical Epidemiology Unit, Lund, Sweden.

Corresponding author, contact information: Vilde Bergstad Larsen, Cluster for Health Services Research, Norwegian Institute of Public Health, Postboks 222, Skøyen, N-0213 Oslo. Visiting address: Sandakerveien 24C, Building D, 0473 Oslo.

Background: We aimed to explore whether children in hospital care with COVID-19 have increased post-discharge health care use when compared to children in hospital care with 1) RSV infection, and 2) other RTIs.

Methods: In 34,214 children aged 1 month to 5 years who were registered with one or more hospital contacts with COVID-19 (N=128), RSV infection (N=4,009) or other RTIs (upper- and lower unspecified RTI as well as influenza) (N=34,457) (January 1st, 2017 to September 20th, 2021), we used a pre-post study design to investigate the individual all-cause primary and specialist health care use from 12 weeks prior to hospital admission, to 12 weeks after hospital discharge, stratified on infants (1-12 months) and toddlers (1-5 years).

Findings: We found a slight increase in primary health care use in the first four weeks after discharge for children aged 1-12 months with COVID-19 when compared to children with RSV infection (0.064 percentage points, 95% CI 0.02-0.126, 0.52% relative increase). For children aged 1-5 years, COVID-19 discharge was associated with a 1-4 weeks increase in primary health care use when compared to children with RSV infection (0.068 percentage points, 95% CI 0.022-0.144, 0.53% relative increase) and other RTI (0.046 percentage points, 95% CI 0.002-0.091, 0.45% relative increase). For children aged 1-12 months in hospital care with COVID-19, we found a similar-magnitude-increase in post-discharge inpatient specialist care use, which lasted for 12 weeks.

Interpretation: Our findings imply no severe impact on health care use after hospitalization with COVID-19 compared to hospitalization with RSV infection or other RTIs. The etiological mechanisms for potentially worse post-hospitalization complaints or health-seeking behavior for COVID-19 than for other RTIs in children should be further explored.

Keywords: Respiratory tract infection, COVID-19, respiratory syncytial virus, hospital admission, health care use

Introduction

The infection prevention and control (IPC) measures initially implemented to limit transmission of SARS-CoV-2 during 2020 and 2021 resulted in both a lower incidence of COVID-19 and lower circulation of other respiratory tract viruses.[1,2] Currently, most IPC measures have been eased in Western countries due to high vaccine coverage. However, children remain unvaccinated, and many children may have a so-called immunity debt due to lack of viral exposure.[3,4] Hence, a large increase in hospital contacts due to severe COVID-19, respiratory syncytial virus (RSV) infection, or other respiratory tract infections (RTIs) may be expected.[5,6]

The extent to which children with severe COVID-19 have elevated use of primary care when compared to children severely ill with other viral infections, such as RSV infection or influenza, is unknown. Hospital care with RSV infection has been reported to have a significant impact on post-disease health and morbidities in young children (caregivers report poorer health at 60 days after discharge), yet its impact when compared to the impact of COVID-19 has never been studied.[7]

Utilizing an observational pre-post design based on nation-wide individual-level data, we aimed to explore whether, and for how long, COVID-19 resulting in hospital contact gives an increase in individual health care use in comparison to hospital contacts with RSV infection and other RTI in children aged 1-12 months and 1-5 years. Improved knowledge of how post-COVID health compares to post-RSV infection health, and post-RTI health, is important when developing and prioritizing vaccination of young children against RSV, influenza, and SARS-CoV-2.

Methods and data

Using a pre-post study design with two comparison groups, we utilized nation-wide individual-level data from the Norwegian Emergency Preparedness Register, Beredt C19 (see Fig. S1 for registries used from within Beredt C19).[8]

Our study sample included all children aged 1 month to 5 years who were residents in Norway and who had a hospital contact (proxy for severe disease) with COVID-19, RSV infection, or other RTI, between January 1st, 2017 and September 20th, 2021, and who could be followed for at least 4 weeks before the day of hospital admission and after the day of discharge (Fig. S2). All children were followed from January 1st, 2017 (study start), date of birth, or date of immigration, whichever came last. Similarly, all children were followed until October 18th, 2021 (study end), until the day they turned 6 years old, death, or emigration, whichever came first. We divided our sample into two age groups (1-12 months and 1-5 years old at date of admission).

Eligible hospital contacts were identified using International Classification of Diseases (ICD-10) diagnostic codes, categorized into three mutually exclusive diagnosis categories: COVID-19, RSV infection, and other RTI (both primary and secondary diagnoses included, see Table S1 for full list of included ICD-10 codes). We included both inpatient and outpatient hospital contacts, independent of duration and urgency. The terms admission and discharge are used to describe the first and last day of a hospitalization spell. Hospitalization spells with any

mention of the included diagnostic codes that occurred with less than two calendar days in between, were coded as one hospitalization spell, i.e., with the same admission ID and date of admission and discharge. In case of multiple mentions of different diagnosis categories within the same hospitalization spell, we chose the most specific RTI code (i.e., with known pathogen). Children with multiple hospitalization spells during our study period reentered the study after a washout period of 6 months.

We constructed our data in a relative-week panel structure (relative to the admission date and the discharge date of the hospitalization). The outcome variables were both all-cause primary health care use (including consultations at general practitioner and emergency ward) and all-cause specialist health care use (overall, and separated into inpatient and outpatient services) for three months prior to hospital admission and three months after hospital discharge. To estimate how much more, or less, frequent utilization of health care services was for children hospitalized with COVID-19 compared to 1) children hospitalized with RSV infection, and 2) children hospitalized with other RTIs, we used a difference-in-differences (DiD) design with separate estimates for each month (defined as 4-week period) after hospital discharge. Hence, we extended the traditional DiD design from one to three post-treatment periods: 1-4 weeks; 5-8 weeks; and 9-12 weeks after discharge, compared to the baseline 12 weeks prior to admission. The statistical models were estimated using linear regression with robust standard errors on the individual level and adjusting for calendar month and year to account for any seasonal variation in health care utilization.[9-12]

Ethics

The establishment of an emergency preparedness register forms part of the legally mandated responsibilities of The Norwegian Institute of Public Health (NIPH) during epidemics. Institutional board review was conducted, and The Ethics Committee of South-East Norway confirmed (June 4th, 2020, #153204) that external ethical board review was not required.

Results

Among 12,058 children aged 1-12 months and 23,682 children aged 1-5 years who were registered with 38,594 hospitalizations in the period from January 1st, 2017 to September 20th, 2021, we studied primary and specialist health care use after 128 hospitalizations with COVID-19 (among 120 children), 4,009 hospitalizations with RSV infection (among 3,873 children), and 34,457 hospitalizations (among 31,747 children) with other RTIs (Table S2). In total, 25 children aged <18 years were registered with codes indicative of Multiorgan Inflammatory Syndrome after COVID-19 (MIS-C) in Norway in June 2021 (ref), and no further analyses of this subgroup was undertaken due to the even lower number that can be expected when restricting to our age group of interest.[13]

Crude all-cause primary and specialist health care use

Children hospitalized with RSV infection had on average slightly higher pre-admission levels of primary health care use than children hospitalized with COVID-19 or other RTIs in the same age group (Table S3). The lowest average level of primary health care use prior to admission was found for children aged 1-5 years hospitalized with COVID-19 (Table S3). Use of primary health care increased for all diagnosis groups and both age groups in the week before admission (Fig. 1). This is to be expected, because hospital care depends on referral from primary care at least when the degree of urgency is low. Within the first four weeks of

discharge, children with RSV infection and other RTIs had resumed to pre-admission levels of primary care use, while it remained elevated until weeks 5-8 for the children with COVID-19 (Fig. 1; Table S3).

The average weekly utilization of specialist care prior to admission was similar to the level of primary health care use for all groups, except for children aged 1-5 years with RSV infection or other RTI (Fig. 1; Table S3). For most children, we observed an increase in the crude percentage that utilized specialist health care the week after discharge (Fig. 1). Like primary health care use, utilization of specialist health care resumed to pre-admission levels within 5-8 weeks of discharge for most diagnosis and age groups (Table S3).

[Figure 1]

Fig. 1 Crude share (%) of primary and specialist health care use in the weeks before and after hospitalization. 95 % confidence intervals (CI) calculated using the Wilson method for binomial proportions. For each week (7-day period) before and after hospitalization, the denominator equaled the number of children who could be observed the given week and the numerator equaled the number of children who had at least one health care contact (calculated separately for age and diagnosis groups).

Differences-in-differences analyses, all-cause primary care use

Children aged 1-12 months hospitalized with COVID-19 had a short-term increase in primary care use after discharge compared to same-aged children hospitalized with RSV infection (0.064 percentage points, 0.52 % relative increase), corresponding to an average weekly increase of approximately 6 consultations per 10,000 children hospitalized with COVID-19 (Table 1). Similarly, children aged 1-5 years also had an increase in utilization of primary health care the first four weeks after discharge, when compared to children hospitalized with RSV infection (0.068 percentage points, 0.53 % relative increase) or other RTIs (0.046 percentage points, 0.45 % relative increase) (Table 1). These differences corresponded to average weekly increases of approximately 7 and 5 consultations per 10,000 children hospitalized with COVID-19, respectively. After 5 weeks of discharge, there were no differences in utilization of primary health care for either age group.

Table 1: Impacts of being hospitalized with COVID-19 on primary health care use in children, using children hospitalized with RSV infection and other RTIs as comparison group.

	Week 1-4		Week 5-8		Week 9-12	
	β	95 % CI	β	95 % CI	β	95 % CI
1-12 months						
RSV infection	0.064	0.002-0.126	-0.001	-0.065-0.062	-0.019	-0.078-0.04
Other RTI	0.044	-0.013-0.101	-0.019	-0.077-0.04	-0.025	-0.084-0.033
1-5 years						
RSV infection	0.068	0.022-0.144	0.034	-0.007-0.076	0.016	-0.019-0.05
Other RTI	0.046	0.002-0.091	0.022	-0.019-0.063	0.003	-0.027-0.032

Notes: Differences-in-differences estimates (β, in percentage points) for the change in the percentage of children utilizing primary health care per week after the day of discharge. The 12-week pre-admission period for the comparison group (RSV infection or other RTI) is used as reference category. Average primary care use in the 12-week pre-admission period by age and diagnosis group is given in Table S3.

Differences-in-differences analyses, all-cause specialist care use

Children hospitalized with COVID-19 had no increased use of all-cause specialist care services (inpatient and outpatient studied together) after discharge when compared to children hospitalized with RSV infections or other RTIs (Table 1). However, when restricting to inpatient health care use, we observed that children hospitalized with COVID-19 had an increase in post-discharge utilization both for weeks 1-4 (0.044 percentage points, 0.95 % relative increase), 5-8 (0.037 percentage points, 0.80 % relative increase) and 9-12 (0.038 percentage points, 0.82 % relative increase) when compared to children hospitalized with RSV infection, yet only for the youngest children (1-12 months) (Table S5). This corresponds to a weekly average increase of approximately 4 inpatients per 10,000 children (Table S5). No increase was observed for outpatient health care use (Table S5).

Table 2: Impacts of being hospitalized with COVID-19 on specialist health care use in children, using children hospitalized with RSV infection and other RTI as comparison group.

	Week 1-4		Week 5-8		Week 9-12	
	β	95 % CI	β	95 % CI	β	95 % CI
1-12 months						
RSV infection	0.041	-0.002-0.084	0.014	-0.047-0.074	0.028	-0.041-0.097
Other RTI	0.02	-0.021-0.06	-0.006	-0.057-0.045	0.011	-0.046-0.067
1-5 years						
RSV infection	0.005	-0.037-0.047	-0.018	-0.07-0.034	-0.014	-0.062-0.034
Other RTI	0.014	-0.026-0.054	-0.017	-0.072-0.038	-0.025	-0.069-0.02

Notes: Differences-in-differences estimates (β, in percentage points) for the change in the percentage of children utilizing specialist health care per week after the day of discharge. The 12-week pre-admission period for the comparison group (RSV infection or other RTI) is used as reference category. Average specialist care in the 12-week pre-admission period by age and diagnosis group is given in Table S3.

Discussion

In the current study of 34,214 children aged 1 month to 5 years, we found a minor increase in primary health care use in the first four weeks after hospitalization with COVID-19 for children aged 1-12 months, compared to children hospitalized with RSV infection, and for children aged 1-5 years, compared to children hospitalized with RSV infection and other RTIs. This difference dissipated after five weeks of discharge. Further, 1-12-month-olds hospitalized with COVID-19 had an increase of similar magnitude in inpatient specialist care use when compared to 1-12-month-olds hospitalized with RSV infection, lasting for 12 weeks after discharge. Since COVID-19 hospitalization among children was very rare, these estimates do not indicate any sizable, lasting impact on health care use after COVID-19 compared to RSV infection or other RTI.

To our knowledge, the present study is the first to compare the severity of the major RTIs in terms of post-disease health care use. By including hospital contacts for both the novel SARS-CoV-2 virus, RS virus and other RT viruses including influenza, our findings form a significant contribution to the understanding of the burden of common RTIs on the health care services once disease control measures have been eased.

Interpretation and comparison with other studies

The present study sheds new light on previous studies reporting that hospital care with RSV infection has a significant impact on post-disease health and morbidities in young children (caregivers report poorer health at 60 days after discharge).[7] Here, we could compare the rather serious RSV hospitalization with hospitalizations for COVID-19 and other RTI. Further, besides shedding novel light on post-discharge health care use, we also show that hospitalization for RSV infection and other RTIs is considerably more common than hospitalization for COVID-19 among young children. When it comes to reducing the burden on the health services, these observations indicate that targeted interventions against RSV and other RTI should receive priority over COVID-19 in this age group.

The slight increase in primary health care use after hospitalization with COVID-19 compared to after RSV infection or other RTIs are in line with results from our recent preprint study showing that children with mild COVID-19 had increased utilization of primary health care after infection, when compared to same-aged non-infected children.[9] This does not necessarily indicate that children with COVID-19 have more severe post-disease symptoms than children with other diagnoses. Rather, it may reflect differences in health-seeking behavior or the behavior of health care services when facing the new SARS-CoV-2 virus compared to the more well-known infections due to e.g., RSV. However, we now show across two different studies with four different comparison groups, that children with mild and severe COVID-19 may be worse off than both untested children, children testing negative[9] and, as shown in the current study, children who are hospitalized for other RTIs. Although we did not aim to shed light on long-term complaints or clinical consequences in any of these studies, the etiological mechanisms for potentially worse complaints and/or more health-seeking behavior following COVID-19 among children than among healthy children or children ill with other diseases, deserves further research attention.

Strengths and limitations

An important strength of our study is the utilization of routinely collected individual-level data from nation-wide registers that are mandated by law, ensuring representativeness and no

attrition. Relatedly, our use of two comparison groups (RSV infection and other RTIs) as well as several post-discharge time periods strengthens the robustness of our findings.

Some limitations to our data and results should be noted. First, severe COVID-19 requiring hospitalization is extremely rare in children, which is reflected in the sample size and statistical strength even in our nation-wide population. Along this line, due to the suppressed incidence of hospitalizations for RSV and other RTI because of disease control measures during 2020 and 2021, we had to compare the incidence of the very few hospitalizations for COVID-19 during these years, with the much higher incidence of RSV infection and other RTI hospitalizations during 2017-2019. This was handled by the inclusion of seasonal variations (calendar month and year) in our models. A second limitation may be that for children in most age and diagnosis groups, we found similar utilization levels for specialist health care as for primary health care in the weeks prior to hospital admission. This may indicate that children who need hospitalization due to the included diseases generally have poorer health and thus different patterns of health-seeking behavior than the general population. Thus, hospitalization may not serve as a proxy for disease severity, but rather reflect the underlying health of the child. Lastly, our 12-week observation period may be too short to capture postviral conditions, such as RSV followed by repeated episodes of bronchopulmonal obstructions.

Conclusion

We find a minor increase in primary health care use in the first four weeks after hospitalization with COVID-19 for children aged 1-12 months, compared to children hospitalized with RSV infection, and for children aged 1-5 years, compared to children hospitalized with RSV infection or other RTIs. The increases correspond to between 5 and 7 additional care consultations per 10,000 children and were reduced to zero at five weeks after discharge. We also find a similar increase in specialist care for children aged 1-12 months after hospitalization with COVID-19 lasting for up to 12 weeks after discharge, when compared to children hospitalized with RSV infection. The increase corresponds to 4 additional consultations per 10,000 children. Because severe RSV infection and other RTIs are much more common than severe COVID-19 in children aged 0-5 years, our results support that targeted interventions such as vaccine development for RSV and influenza may be prioritized higher than vaccine development for COVID-19 among children. The etiological mechanisms for potentially worse complaints following hospitalization with COVID-19 than following hospitalization with other RTIs in children should be further explored.

List of references

1. van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter?. *Euro Surveill*, 2021; **26**(29). DOI: https://doi.org/10.2807/1560-7917.ES.2021.26.29.2100639
2. Emborg H, Carnahan A, Bragstad K, et al. Abrupt termination of the 2019/20 influenza season following preventive measures against COVID-19 in Denmark, Norway and Sweden. *Euro Surveill*, 2021; **26**(22). https://doi.org/10.2807/1560-7917.ES.2021.26.22.2001160
3. Hatter L, Eathorne A, Hills T, Bruce P, Beasley R. Respiratory syncytial virus: paying the immunity debt with interest. *The Lancet Child and Adolescent Health* 2021; **5**(12): E44—E45. DOI: https://doi.org/10.1016/S2352-4642(21)00333-3.
4. Cohen R, Ashman M, Taha M, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?. *Infectious Diseases Now* 2021; **51**(5): 418–423. DOI: https://doi.org/10.1016/j.idnow.2021.05.004.
5. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. *Proceedings of the National Academy of Sciences* 2020, **117**(48): 30547–30553. DOI: https://doi.org/10.1073/pnas.2013182117.
6. Norwegian Institute of Public Health. Risiko ved andre luftveisinfeksjoner enn covid-19 høsten og vinteren 2021/2022. [Risk of other respiratory tract infections than COVID-19 fall and winter 2021/2022]. Oslo, Norway; 2021. https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2021/risiko-ved-andre-luftveisinfeksjoner-enn-covid-19-hosten-og-vinteren-2021-2022-rapport-2021.pdf
7. Leidy NK, Margolis MK, Marcin JP, et al. The impact of severe respiratory syncytial virus on the child, caregiver, and family during hospitalization and recovery. *Pediatrics* 2005; **115**(6): 1536–46. DOI: https://doi.org/10.1542/peds.2004-1149.
8. Norwegian Institute of Public Health [Internet]. Emergency preparedness register for COVID-19 (Beredt C19) [cited 2021 Nov 17]. https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/
9. Magnusson K, Skyrud KD, Suren P, et al. Health care use up to 6 months after COVID-19 in 700.000 children and adolescents: a pre-post study. *medRxiv* 2021; doi: https://doi.org/10.1101/2021.06.02.21258211 [preprint].
10. Dimick JB, Ryan AM. Methods for Evaluating Changes in Health Care Policy: The Difference-in-Differences Approach. *JAMA* 2014; **312**(22): 2401—2402.
11. Angrist, J D. Pischke, J-S. Most Harmless Econometrics An Empiricist's Companion. Princeton University Press, 2009.
12. Wing C, Simon K, Bello-Gomez RA. Designing difference in difference studies: best practices for public health policy research. *Annu Rev Public Health* 2018; **39**; 453—469.
13. Norwegian Institute of Public Health. Svar på oppdrag 37 – Koronavaksinasjon av ungdom. [Response to assignment 37 – Coronavirus vaccination of youth]. Oslo, Norway; 2021. https://www.fhi.no/contentassets/3596efb4a1064c9f9c7c9e3f68ec481f/2021-07-05-oppdrag-37_vaksinasjon-av-16-17-aringer.pdf

Data sharing statement

The individual-level data used in this study are not publicly available due to privacy laws, but the individual-level data in the registries compiled in Beredt C19 are accessible to authorized researchers after ethical approval and application to helsedata.no administered by the Norwegian Directorate of eHealth.


1−12 months
1−5 years
Crude share (%) of all−cause primary health care use
0
20
40
−12
−8
−4
0
4
8
12
1−12 months
1−5 years
Crude share (%) of all−cause specialist care use
0
10
20
30
Week
COVID−19
Other RTI
RS−virus infection